Localized scleroderma in childhood: A report of 30 cases

https://doi.org/10.1016/0049-0172(94)90028-0Get rights and content

Abstract

Localized scleroderma (LS), a rare disease that occurs primarily in the pediatric age group, differs from systemic sclerosis (SSc) in that it is usually limited to the skin and subcutaneous tissue and is only rarely associated with systemic manifestations. The authors' experience with pediatric LS seen in 30 patients at a tertiary care center was reviewed: 26 had linear scleroderma, 19 on an extremity and 7 on the face; 3 had morphea; and 1 had generalized morphea. Antinuclear antibodies were present in 76% and rheumatoid factor in 39%. Five of 19 patients with linear scleroderma that involved an extremity had growth failure in that limb, and 1 required surgery. Sclerodermatous involvement over a joint resulted in limited range of movement in 6 patients, and 1 required surgery. One of the 30 patients developed SSc and polymyositis. There was difficulty in evaluating disease activity and hence in evaluating treatment. This experience with a large patient population suggests that LS, although usually a self-limiting disease, can result in significant morbidity.

References (88)

  • HK Kornreich et al.

    Scleroderma in childhood

    Arthritis Rheum

    (1977)
  • E Torok et al.

    Morphoea in children

    Clin Exp Dermatol

    (1986)
  • JA Fry et al.

    Intracranial findings in progressive facial hemiatrophy

    J Rheumalol

    (1992)
  • N Birdi et al.

    Localized scleroderma progressing to systemic disease. (Case report and review of literature)

    Arthritis Rheum

    (1993)
  • HB Christianson et al.

    Localized scleroderma. A clinical study of 235 cases

    AMA Arch Dermatol

    (1956)
    HB Christianson et al.

    Localized scleroderma. A clinical study of 235 cases. erratum

    AMA Arch Dermatol

    (1957)
  • V Falanga et al.

    Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities

    Ann Intern Med

    (1986)
  • A Silman et al.

    An epidemiological study of scleroderma in the West Midlands

    Br J Rheumatol

    (1988)
  • V Falanga

    Localized scleroderma

    Med Clin North Am

    (1989)
  • R Fleischmajer et al.

    Scleroderma, eosinophilia, and diffuse fasciitis

    Arch Dermatol

    (1978)
  • MA Rodriguez-Prieto et al.

    Sclerodermiform linear atrophy caused by triamcinolone

    Med Cutan Ibero Lat Am

    (1985)
  • JG Clark et al.

    Bleomycin-induced synthesis of type I procollagen by human lungs and skin fibroblasts in culture

    Biochim Biophys Acta

    (1980)
  • CM Black et al.

    Geneticsusceptibility to scleroderma-like syndrome induced by vinyl chloride

    Lancet

    (1983)
  • V Lecerf et al.

    Negativity of Borrelia burgdorferi serology in scleroderma en plaques

    Ann Dermatol Venerol

    (1989)
  • V Lecerf et al.

    Borrelia burgdorferi and localized scleroderma

    Arch Dermatol

    (1989)
  • P Langevitz et al.

    HLA alleles in systemic sclerosis: Association with pulmonary hypertension and outcome

    Br J Rheumatol

    (1992)
  • S Panicheewa et al.

    Diffuse systemic sclerosis and related diseases in Thailand

    Clin Rheumatol

    (1991)
  • C Black et al.

    The immunogenetic background of scleroderma—An overview

    Clin Exp Dermatol

    (1992)
  • RC Wuthrich et al.

    Localized scleroderma

    Arch Dermatol

    (1975)
  • MA Wadud et al.

    Familial localised scleroderma from Bangladesh: Two case reports

    Bangladesh Med Res Comic Bull

    (1989)
  • J Nilsson et al.

    Stimulation of connective tissue cell growth by substance P and substance K

    Nature

    (1985)
  • JC Foreman et al.

    Histamine release and vascular changes induced by neuropeptides

    Agents Actions

    (1983)
  • ES Kimball et al.

    Potentiation of IL-1-induced BALB/3T3 tibroblast proliferation by neuropeptides

    J Immunol

    (1988)
  • ES Kimball et al.

    Substance P, neurokinin A, and neurokinin B induce generation of IL-1-like activity by P388D1 cells. Possible relevance to arthritic disease

    J Immunol

    (1988)
  • M Raszewa et al.

    Sympathetic skin response in scleroderma

    Electronmyogr Clin Neurophysiol

    (1991)
  • MB Kahaleh et al.

    Enhanced platelet adhesion to collagen in scleroderma. Effect of scleroderma plasma and scleroderma platelets

    J Rheumatol

    (1985)
  • DN Sauder

    Interleukin I

    Arch Dermatol

    (1989)
  • A Engström-Laurent et al.

    Raised serum hyaluronate levels in scleroderma: An effect of growth factor induced activation of connective tissue cells?

    Ann Rheum Dis

    (1985)
  • D Degiannis et al.

    Soluble interleukin-2 receptors in patients with systemic sclerosis. Clinical and laboratory correlations

    Arthritis Rheum

    (1990)
  • PJ Clements et al.

    Elevated serum levels of soluble interleukin 2 receptor, interleukin 2 and neopterin in diffuse and limited scleroderma: Effect of chlorambucil

    J Rheumatol

    (1990)
  • RA Hawkins et al.

    In creased dermal mast cell populations in progressive systemic sclerosis: A link in chronic fibrosis?

    Ann Intern Med

    (1985)
  • K Nishioka et al.

    Mast cell numbers in diffuse scleroderma

    Arch Dermatol

    (1987)
  • JR Seibold et al.

    Dermal mast cell degranulation in systemic sclerosis

    Arthritis Rheum

    (1990)
  • HN Claman

    On scleroderma. Mast cells, endothelial cells, and fibroblasts

    JAMA

    (1989)
  • KL Choi et al.

    Cutaneous mast cell depletion and recovering in murine graft-vs-host disease

    J Immunol

    (1987)
  • Cited by (0)

    3

    Drs Silverman and Laxer are Associates of the Arthritis Society.

    1

    From the Divisions of Rheumatology and Dermatology, Department of Paediatrics, and the Department of Pathologe, The Hospital for Sick Children: und the Departments of Paediatrics, Immunology, Medicine, and Pathology, the University of Toronto, Toronto, Canada.

    2

    Dr. Uziel is a Recipient of the Abraham Shore Memorial Medical Fellowship and the American Physicians Fellowship.

    View full text